產品編號 | bs-10581R |
英文名稱 | Rabbit Anti-MMP13 antibody |
中文名稱 | 基質金屬蛋白酶13抗體 |
別 名 | CLG 3; CLG3; Collagenase 3; Collagenase3; MMP13; MMP 13; MMP-13; Matrix Metalloproteinase 13; MMP 13; MMP13_HUMAN. |
Specific References (5) | bs-10581R has been referenced in 5 publications.
[IF=5.026] Ting-ting Yu. et al. Deletion at an 1q24 locus reveals a critical role of long noncoding RNA DNM3OS in skeletal development. Cell Biosci. 2021 Dec;11(1):1-15 IF ; Mouse.
[IF=4.889] Guoqing Li. et al. Teriparatide ameliorates articular cartilage degradation and aberrant subchondral bone remodeling in DMM mice. J ORTHOP TRANSL. 2023 Jan;38:241 IHC ; Mouse.
[IF=3.923] Gong X et al. Synergistically regulated spontaneous calcium signaling is attributed to cartilaginous extracellular matrix metabolism. (2018) J. Cell. Physiol. Oct 28. WB ; Pig.
[IF=3.857] Jin S et al. Sequential Epiphyseal Cartilage Changes of Femoral Heads in C57BL/6 Female Mice Treated with Excessive GlucocorticoidsCartilage.2020 Dec 3;1947603520978574. WB、IHC ; Mouse.
[IF=3.386] Tong, Fei. et al. MiR-466d Targeting MMP13 Promotes the Differentiation of Osteoblasts Exposed to a Static Magnetic Field. BIOTECHNOL BIOPROC E. 2023 Feb;:1-10 WB ; Rat.
|
|
研究領域 | 腫瘤 心血管 細胞生物 信號轉導 細胞骨架 細胞外基質 |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應 | Human,Mouse,Rat (predicted: Rabbit) |
產品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 52kDa |
細胞定位 | 細胞外基質 分泌型蛋白 |
性 狀 | Liquid |
濃 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human MMP13: 251-350/471 |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產品介紹 |
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The protein encoded by this gene cleaves type II collagen more efficiently than types I and III. It may be involved in articular cartilage turnover and cartilage pathophysiology associated with osteoarthritis. The gene is part of a cluster of MMP genes which localize to chromosome 11q22.3. [provided by RefSeq, Jul 2008]. Function: Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process. Subcellular Location: Secreted, extracellular space, extracellular matrix (Probable). Tissue Specificity: Seems to be specific to breast carcinomas. DISEASE: Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age. Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia Similarity: Belongs to the peptidase M10A family. Contains 4 hemopexin-like domains. SWISS: P45452 Gene ID: 4322 Database links: Entrez Gene: 4322 Human Entrez Gene: 17386 Mouse Omim: 600108 Human SwissProt: P45452 Human SwissProt: P33435 Mouse Unigene: 2936 Human Unigene: 5022 Mouse Unigene: 10997 Rat |
產品圖片 |
Sample:
MG63(Human) Cell Lysate at 30 ug
Primary: Anti-MMP13 (bs-10581R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kD
Observed band size: 65 kD
Sample:
Lane 1: Raw264.7 (Mouse) Cell Lysate at 30 ug
Lane 2: Jurkat (Human) Cell Lysate at 30 ug
Lane 3: MCF-7 (Human) Cell Lysate at 30 ug
Lane 4: Molt-4 (Human) Cell Lysate at 30 ug
Lane 5: A431 (Human) Cell Lysate at 30 ug
Primary: Anti-MMP13 (bs-10581RR) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 60 kD
Observed band size: 60 kD
Tissue/cell: human gastric carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-MMP-13 Polyclonal Antibody, Unconjugated(bs-10581R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Paraformaldehyde-fixed, paraffin embedded (rat lung tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MMP13) Polyclonal Antibody, Unconjugated (bs-10581R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
Tissue/cell: mouse lung tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-MMP-13 Polyclonal Antibody, Unconjugated(bs-10581R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
1、抗體溶解方法 | |
2、抗體修復方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關于肽鏈的設計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |